Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma

A. P. Barbour, E. T. Walpole, G. T. Mai, L. Barnes, D. I. Watson, S. P. Ackland, V. Wills, J. Martin, M. Burge, C. S. Karapetis, J. Shannon, L. M. Nott, V. Gebski, M. Oostendorp, K. Wilson, J. Thomas, G. Lampe, J. R. Zalcberg, J. Simes, M. Smithers

    Research output: Contribution to journalArticle

    Abstract

    Resectable oesophageal and gastro-oesophageal junction adenocarci-noma patients (pts) without early metabolic response (EMR) to chemotherapy asdefined by 18-FDG-PET (PET) show poor survival and major histological responserates (RR)<5%. This multicentre trial previously reported changing neoadjuvant ther-apy improved major histological RR for early metabolic non-responders (MNR).Grade 3/4 toxicities were seen in 27% of pts on 5-FUþcisplatin (CF); 42% on doce-taxelþCF (DCF) and 71% on DCFþconcurrent 45Gy radiotherapy (DCFRT).Updated results now report progression-free survival (PFS) and local recurrence.
    Original languageEnglish
    Pages (from-to)viii206-viii207
    Number of pages2
    JournalAnnals of Oncology : Official Journal of the European Society for Medical Oncology
    Volume29
    Issue numberSupp 8
    DOIs
    Publication statusPublished - 1 Oct 2018

    Fingerprint Dive into the research topics of 'Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this

    Barbour, A. P., Walpole, E. T., Mai, G. T., Barnes, L., Watson, D. I., Ackland, S. P., Wills, V., Martin, J., Burge, M., Karapetis, C. S., Shannon, J., Nott, L. M., Gebski, V., Oostendorp, M., Wilson, K., Thomas, J., Lampe, G., Zalcberg, J. R., Simes, J., & Smithers, M. (2018). Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29(Supp 8), viii206-viii207. https://doi.org/10.1093/annonc/mdy282.003